转自:北京商报三次IPO折戟,四川新荷花中药饮片股份有限公司(以下简称“新荷花”)转战港交所。4月16日,北京商报记者注意到,新荷花再次向资本市场发起冲击,不过这次选择的是港交所。然而,新荷花的上市之路并不顺畅,多次冲击资本市场失败的背后,暴露出诸多亟待解决的问题。此外,中药饮片带量采购扩容,对中药饮片生产企业的质量也提出了更高要求,而新荷花多次因质量问题登上国家药监局通报名单,最近一次是在6个月...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.